| Name | JG-98 |
| Description | JG-98 is an allosteric Hsp70 inhibitor, displays high active against the breast cancer cell lines MDA-MB-231 and MCF-7 (EC50s: 0.4/0.7 μM). |
| Cell Research | Cell viability was determined using an MTT colorimetric assay with the following modifications. Briefly, cells (5 x 10^3 ) were plated into 96-well assay plates in 0.1 ml media and allowed to attach overnight. Cells were then treated with compound at various concentrations in 0.2 mL media. After the 72-hour incubation period, cells were washed in PBS (3 x 100 μL), and 10 μL MTT reagent was added with 100 μL fresh media. Cells were then incubated for 4 hr in a humidified chamber at 37 oC with 5% CO2. Insoluble formazan crystals were solubilized by addition of 0.1 mL detergent solution (4 hr at room temp., dark). Resulting colored solutions were then quantified at an absorbance of 570 nm [1]. |
| Animal Research | Briefly, one million MCF7 or HeLa cells in Matrigel were subcutaneously injected bilaterally into 6 week old NCR mice. Once tumors were established, JG-98 (3 mg/kg; n=5) or vehicle control (1:1 PBS: DMSO; n=5) was introduced interperitoneally on days 2, 4 and 6. Tumor growth (10 tumors/5 mice) was measured by caliper every other day [2]. |
| In vitro | JG-98 had a potency of 0.4 ± 0.03 μM against MDA-MB-231 cells and an EC50 value of 0.7 ± 0.2 μM for MCF7 cells. In MDA-MB-231 cells, the treatment of JG-98 activated apoptotic mediators (caspase-3 and PARP). Treatment of both MDA-MB-231 and MCF7 cells with JG-98 strongly affected autophagic flux [1]. JG-98 has antiproliferative activity (EC50 values between 0.3 and 4 μmol/L) across cancer cell lines from multiple origins. JG-98 destabilized FoxM1 and relieved suppression of downstream effectors, including p21 and p27 [2]. |
| In vivo | JG-98 (3 mg/kg) suppressed tumor growth in a HeLa xenograft model, though somewhat less effective [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5 mg/mL (9.35 mM), Sonication is recommended.
|
| Keywords | HSP | Apoptosis | JG-98 | inhibit | Heat shock proteins | Inhibitor |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Apoptosis Compound Library | Cuproptosis Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
